Company / R&D Expense
Candel Therapeutics, Inc. R&D Expense History
FY2021-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$24.5M
FY2023
5-year range
$8.8M / $24.5M
FY2021-FY2023
Trend
+61.5%
vs FY2022
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $9M to $25M over the past 2 years.
Based on SEC 10-K filings.
$25M in FY2023.
Improved from $9M to $25M over the past 2 years.
R&D Expense over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2023, r&d expense increased 61.5% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -5.13 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2023 | $24.5M | +61.5% |
| FY2022 | $15.2M | +73.4% |
| FY2021 | $8.8M | - |
As of FY2023 · SEC 10-K · Updated Jun 24, 2026